Bank of New York Mellon
THRX

Bank of New York Mellon’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Bank of New York Mellon’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-59,553
Closed -$241K – 4375
2023
Q4 		$241K Hold
59,553
– – ﹤0.01% 3892
2023
Q3 		$160K Hold
59,553
– – ﹤0.01% 4016
2023
Q2 		$556K Buy
59,553
+7,691
+15% +$75.8K ﹤0.01% 3527
2023
Q1 		$461K Buy
51,862
+8,369
+19% +$82.1K ﹤0.01% 3532
2022
Q4 		$217K Buy
43,493
+349
+0.8% +$2.04K ﹤0.01% 3935
2022
Q3 		$250K Buy
43,144
+4,333
+11% +$30.6K ﹤0.01% 3920
2022
Q2 		$214K Buy
38,811
+9,432
+32% +$77.9K ﹤0.01% 4027
2022
Q1 		$338K Buy
29,379
+12,219
+71% +$131K ﹤0.01% 3948
2021
Q4 		$217K Buy
+17,160
New +$259K ﹤0.01% 4245

Bank of New York Mellon's THRX Position: Q1 2024 in Review

Bank of New York Mellon sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 59,553 shares — an estimated $241K sold.

Bank of New York Mellon first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $556K in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • Bank of New York Mellon reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 59,553 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $241K.
  • Bank of New York Mellon first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Bank of New York Mellon's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $556K in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Bank of New York Mellon's 13F filing for Q1 2024, filed 25 Apr 2024.